You are here

Pharmacological Therapies for Autism Spectrum Disorder: A Review

Sheena LeClerc PharmD
Deidra Easley PharmD, BCPS


Autism spectrum disorder (ASD) comprises a group of neurodevelopmental disabilities. The Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) includes autism, Asperger’s disorder, and “pervasive personality disorder not otherwise specified” under the umbrella heading of ASD.1 The symptoms of ASD generally appear between the ages of 2 and 3 years.2,3 All children with the disorder experience difficulty in developing social, speech, and behavioral skills. Therefore, behavioral therapy is usually the first-line treatment, with pharmacological therapies added to help patients function in their daily activities.2

This review discusses approved and off-label pharmacotherapeutic options for the various symptoms of ASD.



Risperidone (Risperdal, Janssen, and generics), a second-generation antipsychotic, was the first drug approved by the Food and Drug Administration (FDA) to treat autism-related irritability.4 Its 2006 approval applied to children 5 years of age and older.

McCracken et al. conducted an eight-week, randomized, double-blind, placebo-controlled trial of risperidone (0.5 to 3.5 mg daily) in 101 children 5 to 17 years of age.5 This study showed improvements in the number of tantrums, aggressive episodes, and self-injurious behaviors in children with ASD treated with risperidone compared with those given placebo, as measured by the irritability scale of the Aberrant Behavior Checklist (ABC) and by the Clinical Global Impressions–Improvement (CGI–I) scale (P < 0.001). The most common adverse effects (AEs) observed in the risperidone arm included increased appetite, dizziness, drooling, drowsiness, and fatigue (P < 0.05 versus placebo for each). The authors noted that the study’s short duration did not allow tardive dyskinesia—a potential consequence of risperidone therapy—to occur.

Troost and colleagues conducted a 32-week placebo-discontinuation trial to assess the long-term efficacy and safety of risperidone in children (ages 5 to 17 years) with ASD accompanied by severe tantrums, aggression, or self-injurious behavior.6 Thirty-six subjects received eight weeks of open-label treatment with risperidone. The responders (n = 26) continued treatment for another 16 weeks, followed by a double-blind discontinuation phase (n = 24) consisting of either three weeks of taper and five weeks of placebo only or continuing use of risperidone. Daily doses of risperidone ranged from 0.5 to 3.5 mg.

Patients treated with risperidone showed decreased levels of irritability (P = 0.0001), social withdrawal (P = 0.0001), stereotypy (P = 0.047), hyperactivity (P = 0.033), and inappropriate speech (P = 0.033) compared with those given placebo. Risperidone was also superior to placebo in preventing the relapse of ASD (P = 0.049). Weight gain, increased appetite, anxiety, and fatigue were the most common AEs.

Sharma et al.7 conducted a meta-analysis of 16 open-label and six placebo-controlled studies of risperidone in children with ASD published after 2000. The authors calculated effect sizes for each reported measure within a study to determine an average effect size per study. They found that the trials’ outcome measures demonstrated a mean improvement in problematic behaviors equaling one standard deviation, thus supporting the effectiveness of risperidone in managing behavioral problems and symptoms in children with ASD. In all of the studies, rapid weight gain was the most common AE associated with risperidone.


The FDA approved the psychotropic drug aripiprazole (Abilify, Bristol-Myers Squibb, and generics) in 2009 for the treatment of irritability in children (ages 6 to 17 years) with ASD.8 The drug is also indicated for the treatment of schizophrenia, bipolar I disorder, major depressive disorder, and Tourette’s syndrome. Its mechanism of action is unknown but may involve a combination of partial agonist activity at dopamine type 2 (D2) and serotonin type 1A (5-HT1A) receptors and antagonist activity at 5-HT2A receptors.9

The safety and tolerability of aripiprazole were evaluated in a 52-week, open-label study involving 330 children (ages 6 to 17 years) with ASD who were treated for irritability.10 All of the subjects were started on a dosage of 2 mg per day and were then titrated to target dosages of 5, 10, or 15 mg per day. AEs occurred in 87% of the subjects. The most common AEs included weight increase, vomiting, nasopharyngitis, increased appetite, pyrexia, upper respiratory tract infection, and insomnia. Discontinuations due to AEs occurred in 11% of the subjects, mostly because of weight gain and aggression.

A post hoc analysis of two eight-week, controlled clinical studies focused on the effects of aripiprazole on health-related quality of life during treatment for irritability in 316 children (ages 6 to 17 years) with ASD.11 Aripiprazole was associated with significantly greater improvement than placebo in Pediatric Quality of Life Inventory scores. The most common AEs included fatigue, somnolence, sedation, extrapyramidal symptoms, and weight gain.

These eight-week clinical trials were also the subject of a meta-analysis by Ching and colleagues.12 The authors reported a mean improvement of 6.17 points on the ABC irritability subscale, 7.93 points on the ABC hyperactivity subscale, and 2.66 points on the stereotypy subscale in children treated with aripiprazole compared with those given placebo. Children treated with aripiprazole had a greater increase in weight, with a mean gain of 1.13 kg, compared with the placebo group. Aripiprazole-treated children also had a higher risk ratio for sedation (4.28) and tremor (10.26).


Before the approval of risperidone and aripiprazole for the treatment of ASD symptoms, the second-generation antipsychotic agent clozapine (Clozaril, Novartis, and generics) had been used for aggression and tantrums.67

Clozapine is indicated for the treatment of schizophrenia and for reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder. Its therapeutic efficacy in schizophrenia is believed to be mediated through antagonism of the D2 and 5-HT2A receptors. The drug also acts as an antagonist at adrenergic, cholinergic, histaminergic, and other dopaminergic and serotonergic receptors.13

The effectiveness of clozapine in limiting ASD-related disruptive behaviors was the subject of a retrospective analysis by Beherec and colleagues.14 They found that treatment with clozapine resulted in a significant twofold decrease in the number of days with aggression, a decrease in the number of psychotropic drugs used, and a decrease in the dose of the antipsychotic drugs. The authors also found, however, that clozapine was associated with significant weight gain, metabolic syndrome, and tachycardia. Other studies have reported extrapyramidal symptoms and the need for frequent hematological monitoring. Further, clozapine may cause seizures at high doses. For these reasons, it is seldom used as a first-line treatment in children.15


Haloperidol (Haldol, Janssen/Ortho-McNeil, and generics) belongs to the butyrophenone class and is a highly potent and selective D2 receptor antagonist.16 It is indicated for use in the treatment of schizophrenia and in the control of the tics and vocal utterances of Tourette’s syndrome.17 Haloperidol has a long track record of effective use for the treatment of acute agitation, such as that seen in drug- or alcohol-using patients or in disruptive emergency patients. It is by far the most common first-generation antipsychotic used to treat agitation in the acute setting.18,19

In an early study, Faretra and colleagues20 reported that haloperidol was more effective than the second-generation antipsychotic fluphenazine at reducing aggression in children with autism, although the AEs of treatment included acute dystonic reactions, akathisia, and sedation.

Similarly, Perry et al.21 found that haloperidol remained effective in 60 autistic children (2 to 8 years of age) during six months of treatment. Those with prominent symptoms of irritability, anger, and uncooperativeness were the best responders.

Remington and colleagues22 compared haloperidol with the tricyclic antidepressant clomipramine in the treatment of irritability and other deficits in children and adults (ages 10 to 36 years) with ASD. They, too, reported that the results favored haloperidol. Thirty-six subjects were treated with haloperidol (mean daily dose, 1.3 mg) or clomipramine (mean daily dose, 128.4 mg) for seven weeks. Although clomipramine was comparable with haloperidol in terms of improvement versus baseline, significantly fewer subjects in the clomipramine group compared with those in the haloperidol group were able to complete the study (37.5% versus 69.7%, respectively) because of AEs and efficacy or behavior problems. Moreover, only haloperidol proved superior to baseline on a global measure of autistic symptom severity at the end of the study.

As with all antipsychotic agents, haloperidol has been associated with persistent dyskinesias. In addition, extrapyramidal symptoms have been reported frequently during administration of the drug, often during the first few days of treatment.17


Sertraline (Zoloft, Pfizer/Roerig, and generics), a selective serotonin reuptake inhibitor (SSRI),23 was shown to improve separation anxiety disorder in an 11-year-old girl with Asperger’s disorder.24 In this case report, sertraline was up-titrated over a six-month period to a dosage of 150 mg per day.

No large, well-designed trials have been conducted to support the use of sertraline for the treatment of irritability or aggression in adolescents. In general, SSRIs are not well tolerated in young people because of the drugs’ AEs, which can include increased energy, impulsivity, decreased concentration, diarrhea, and insomnia.25


Risperidone Versus Haloperidol

In an eight-week, double-blind, prospective study, Miral and colleagues26 compared risperidone and haloperidol in 30 children and teenagers (ages 8 to 18 years) with ASD. Both treatments were administered in a once-daily dosage regimen of 0.01 to 0.08 mg/kg per day. Risperidone achieved significant (P < 0.05) reductions from baseline in the sensory motor and language subscales of the Ritvo–Freeman Real-Life Rating Scale. Moreover, compared with haloperidol, treatment with risperidone resulted in a significantly greater reduction in ABC and Turgay DSM-IV Pervasive Developmental Disorder (PDD) scores (P < 0.05 and P < 0.01, respectively). Importantly, risperidone was more effective than haloperidol in treating social behavior, although both drugs had significant effects on the change from baseline (P = 0.0032 and P = 0.0111, respectively). The haloperidol group had significantly (P = 0.0477) more reports of the development or worsening of extrapyramidal symptoms.

In an open-label extension of the study by Miral et al., researchers compared the efficacy and safety of risperidone and haloperidol during 12 weeks of treatment in 28 children and teenagers with ASD.27 In this trial, risperidone (1.2 to 3.8 mg per day) was shown to improve scores on behavioral rating scales, including the ABC and the CGI–I, to a greater degree than haloperidol (0.01 to 0.08 mg per day); the differences, however, were not statistically significant (P = 0.0594). Weight gain occurred more often with haloperidol. The authors concluded that risperidone was more efficacious and better tolerated than haloperidol in the long-term maintenance treatment of ASD.


Oxytocin (Pitocin, Par Sterile Products, and generics) is an endogenous hormone best known for its role in lactation and parturition.28 It has also been found to play a major role in relationship formation and social functioning in both humans and animals.29 Since ASD is associated with impaired social interaction and impaired communication, among other symptoms,1 investigators have looked at the ability of intranasal oxytocin to reduce these deficits.29

Using magnetic resonance imaging, Gordon and colleagues measured changes in brain activity during judgments of socially and nonsocially meaningful pictures in 17 children with ASD after treatment with intranasal oxytocin.30 The investigators found that oxytocin enhanced brain function in these subjects and appeared to improve their evaluations of the socially meaningful stimuli.

Preti and colleagues conducted a systematic review of all randomized controlled trials (RCTs) of intranasal oxytocin in subjects with ASD published from 1990 to 2013.31 Their research yielded seven RCTs involving a total of 101 subjects with the disorder. The authors concluded that these studies provided “potentially promising” findings in measures of emotion recognition and eye gaze, which are impaired early in the course of ASD and might disrupt the learning of social skills in developing children.

In a double-blind, crossover, placebo-controlled study, Guastella et al. demonstrated an improvement in emotional recognition in 16 male youths (ages 12 to 19 years) with ASD treated with intranasal oxytocin.32 The subjects’ treatment responses were evaluated with the Reading the Mind in the Eyes Test, a widely used test of emotion recognition. In comparison with placebo, oxytocin significantly improved performance on this test (P = 0.03).

In a case report from Japan, Kosaka et al.33 described a 16-year-old girl whose social behavior improved after long-term administration of intranasal oxytocin. After six months of treatment, the patient’s ABC score decreased from 69 to 7. The authors concluded that long-term oxytocin nasal spray appeared to be a promising treatment for the social impairments of ASD.


Secretin, another endogenous hormone, regulates exocrine secretions in the stomach, pancreas, and gallbladder. It also acts as a neuropeptide in the central nervous system (CNS).34

A report from the Agency for Healthcare Research and Quality identified eight publications that addressed treatment with human, porcine, or biologic secretin in children with ASD.35 According to the authors, none of these trials demonstrated significantly greater improvements in measures of language, cognition, or autistic symptoms compared with placebo.

Similarly, Williams and colleagues36 reviewed data from 16 clinical trials of intravenous secretin in a total of 900 children with ASD and found no evidence that the hormone was effective in that setting. They concluded that secretin should not be recommended or administered as an ASD treatment.



Methylphenidate (Ritalin, Novartis; Concerta, Janssen; and generics) is a mild CNS stimulant indicated for attention-deficit disorders and narcolepsy.37,38 The drug is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and to increase the release of these monoamines into the extraneuronal space.38

Handen et al. evaluated methylphenidate in a double-blind, placebo-controlled, crossover study of 13 children (6 to 11 years old) with autism and symptoms of attention-deficit/hyperactivity disorder (ADHD).39 Methylphenidate was administered at doses of 0.3 and 0.6 mg/kg. Eight of the subjects showed significant improvements in hyperactivity and impulsivity, as measured by the Conners Hyperactivity Index. However, no changes were found on the Childhood Autism Rating Scale (CARS). More than 50% of the subjects in each dosage arm experienced decreased appetite, increased irritability, social withdrawal, and restlessness.

In another blinded crossover study, Posey and colleagues40 evaluated methylphenidate in 66 children (mean age, 7.5 years) with pervasive developmental disorders (PDDs) and significant hyperactive–inattentive symptoms. Methylphenidate was administered at doses of 0.125, 0.25, or 0.5 mg/kg at 8 a.m. and at noon, with an additional half dose late in the afternoon. Subjects in all three treatment arms showed significant improvements in ADHD symptoms (P < 0.04, P < 0.001, and P < 0.001, respectively). However, only the medium and high doses of methylphenidate significantly improved inattention (P = 0.15, P < 0.001, and P < 0.001) and hyperactivity/impulsivity (P = 0.80, P < 0.001, and P < 0.001). There were no significant effects on oppositional defiance disorder or stereotyped and repetitive behavior. The most common AE was irritability.

The Research Units on Pediatric Psychopharmacology Autism Network41 evaluated methylphenidate in 72 children (5 to 14 years of age) with PDDs accompanied by moderate-to-severe hyperactivity. Treatment was based on weight and ranged from 7.5 mg per day to 50 mg per day in divided doses. Subjects who tolerated the test dose (n = 66) were assigned to receive placebo for one week and then three methylphenidate doses in random order during a double-blind crossover phase. Children who responded to methylphenidate then entered eight weeks of open-label treatment at the individually determined best dose.

Methylphenidate was superior to placebo on the teacher-rated hyperactivity subscale of the ABC (the trial’s primary outcome measure). Thirty-five of the 72 enrolled subjects (49%) were classified as methylphenidate responders. AEs led to treatment discontinuation in 13 of the 72 subjects (18%).


Venlafaxine (Effexor, Pfizer/Wyeth, and generics) is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder.42

In three clinical cases described by Carminati et al.,43 all of the subjects responded to low-dose venlafaxine (18.75 mg per day), as determined by their CGI scores. The first case involved a 17-year-old boy with autism and severe behavioral symptoms, including aggression, self-injurious behavior, and hyperactivity; the second case involved a 23-year-old woman with autism hyperactivity; and the third case involved a 17-year-old girl with the same disorder. The subjects were followed for 18, 36, and six months after treatment initiation, respectively. The authors concluded that low-dose venlafaxine, in addition to the patient’s current antipsychotic regimen, could improve self-injurious behavior and ADHD-like symptoms.



Fluoxetine (Prozac, Lilly, and generics) is a selective serotonin reuptake inhibitor (SSRI) indicated for acute and maintenance treatment of major depressive disorder; acute and maintenance treatment of obsessive compulsive disorder; acute and maintenance treatment of bulimia nervosa; and acute treatment of panic disorder, with or without agoraphobia.44

Hollander and colleagues22 reported improvement in repetitive behaviors among adults with ASD treated with fluoxetine (20 to 80 mg per day). Thirty-seven adults (18 to 60 years of age) were treated with fluoxetine (n = 22) or placebo (n = 15) for 12 weeks. The fluoxetine dosage started at 10 mg per day and was increased, as tolerated, up to 80 mg per day. Repetitive behaviors (obsessive-compulsive symptoms) showed improvement in 50% of the fluoxetine group compared with 8% of the placebo group. The most common treatment-related AEs were mild-to-moderate insomnia, headache, and dry mouth.

In the Study of Fluoxetine in Autism (SOFIA), however, a low-dose, melt-in-the-mouth formulation of the drug was found to be no more effective than placebo in treating repetitive behaviors in children and adolescents (5 to 17 years of age) with ASD.45


Citalopram (Celexa, Forest Pharmaceuticals, and generics) is an SSRI indicated for the treatment of depression.46

In a randomized, placebo-controlled trial, King and colleagues47 found that citalopram was ineffective in treating children (5 to 17 years old) with ASD, including Asperger’s disorder and unspecified developmental disorders. A total of 149 subjects received either citalopram 10 mg (n = 73) or placebo (n = 76) for 12 weeks. There was no significant difference between citalopram and placebo in the rate of positive response on the CGI–I subscale (32.9% versus 34.2%, respectively). Moreover, citalopram was significantly more likely to be associated with AEs, particularly increased energy level, impulsiveness, decreased concentration, hyperactivity, stereotypy, diarrhea, insomnia, and dry skin or pruritus.


Bumetanide (generics) is a potent loop diuretic indicated for the treatment of edema associated with congestive heart failure, hepatic disease, and renal disease (including nephrotic syndrome).48

A small, double-blind, randomized, placebo-controlled study conducted in Europe and the U.S. evaluated 60 children (3 to 11 years of age) with ASD who were treated with bumetanide 1 mg or placebo for three months.49 Bumetanide was associated with significantly reduced scores on the CARS (P < 0.004) and the CGI (P < 0.017).

The only AE of active treatment was occasional mild hypokalemia, which was treated with supplemental potassium.49 Bumetanide, however, is known to cause profound diuresis, with water and electrolyte depletion. Therefore, careful medical supervision is required during treatment, and the dose and dosage schedule must be adjusted to the individual patient’s needs.48



Memantine (Namenda, Forest Pharmaceuticals, and generics) is an N-methyl-D-aspartate (NMDA) receptor antagonist indicated for the treatment of moderate-to-severe dementia of the Alzheimer’s type. Persistent activation of NMDA in the CNS is believed to contribute to the symptoms of Alzheimer’s disease.50

Owley and colleagues51 evaluated memantine (0.04 mg/kg) in an eight-week, open-label pilot study of 14 children (ages 3 to 12 years) with PDDs. Twelve children completed the study. A significant improvement from baseline was noted on the Children’s Memory Scale Dot Learning Subtest, a memory evaluation (P = 0.021). However, there were no significant differences from baseline on measures of expressive language, receptive language, and nonverbal IQ. Several ABC subscales, including hyperactivity, lethargy, and irritability, also failed to show significant improvements from baseline. Four of the 14 enrolled subjects showed minimal improvement on the CGI–I test, and none was judged to be “much improved” or “very much improved.”


The acetylcholinesterase inhibitor rivastigmine (Exelon, Novartis, and generics) is indicated for the treatment of mild-to-moderate dementia of the Alzheimer’s type and mild-to-moderate dementia associated with Parkinson’s disease. Although the drug’s precise mechanism of action is unknown, it is thought to exert its therapeutic effects by enhancing cholinergic function.52

Rivastigmine was evaluated in 32 children (ages 3 to 12 years) with ASD to determine whether its use would improve cognition in these patients.53 During the 12-week, open-label study, the subjects received an oral solution of rivastigmine 0.4 mg twice daily. At six weeks, significant improvements from baseline in cognition were seen in the CARS scores and in the Conners’ Parent Rating Scale (both P = 0.001). In addition, significant improvements in cognition were evident at week 12 in the Gardner’s Expressive One-Word Picture Vocabulary test (P = 0.001). AEs were similar to those reported in adults treated with rivastigmine (e.g., nausea, diarrhea, irritability, and hyperactivity).



Mirtazapine (Remeron, Merck, and generics) is an oral tetracyclic antidepressant that enhances central noradrenergic and serotonergic activity.54 In general, antidepressants have been associated with an increased risk, compared with placebo, of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies of subjects with major depressive disorder and other psychiatric disorders. Therefore, this risk must be balanced with the patient’s clinical need when mirtazapine (or any other antidepressant) is used in children, adolescents, or young adults.54

In an open-label study, Poe and colleagues showed that mirtazapine (dosage range, 7.5 to 45 mg per day) was effective in improving insomnia (CGI severity rating, P < 0.004) in 26 children, adolescents, and young adults (4 to 24 years of age) with ASD and other developmental disorders.55 The treatment also significantly improved aggression, self-injury, and irritability scores on the CGI. AEs included increased appetite and transient sedation.


Cortesi et al.56 evaluated a controlled-release formulation of the sleep-promoting hormone melatonin57 in a randomized, placebo-controlled trial involving 160 children (ages 4 to 10 years old) with ASD. Melatonin 3 mg per day (combined with cognitive-behavioral therapy) was compared with placebo for 12 weeks. Treatment was administered at 9 p.m. each day. The active therapy significantly reduced insomnia compared with placebo (P < 0.001), as assessed by the Children’s Sleep Habits Questionnaire. Sleep-onset latency of less than 30 minutes was achieved by 85% of the melatonin-treated patients.

In an open-label, dose-escalation study, Malow and colleagues58 measured sleep latency by actigraphy in 24 children with ASD. The subjects initially received melatonin at a dose of 1 mg 30 minutes before bedtime. The children were evaluated at three-week intervals, and if they did not show a sufficient response (defined as falling asleep within 30 minutes five or more nights per week), the melatonin dose was increased to 3 mg. This process was repeated up to a dose of 6 mg.

Melatonin improved sleep latency as early as one week into the 14-week study, and this improvement was maintained until the end of the trial. Of the 24 children studied, seven obtained a satisfactory response at a dose of 1 mg, 14 at 3 mg, and three at 6 mg.


Aside from Roche,59 pharmaceutical companies have generally shied away from investing in treatments for autism and other ASDs.57 In particular, the pharmaceutical industry has shown risk aversion with regard to conducting research in autism, a disorder with a hazy pathophysiology, a high level of heterogeneity, few clear biomarkers, and poorly developed outcome measures for clinical studies.60

Nevertheless, according to data from the National Institutes of Health,61 approximately 20 clinical trials are evaluating current or potential ASD treatments in the U.S. (Table 1). Oxytocin nasal spray appears to be the most popular therapeutic approach, with at least five early- or mid-stage studies in progress at U.S. centers. Other interesting drugs under investigation for the treatment of ASD include the following:

  • Acamprosate (Campral, Forest Pharmaceuticals), a synthetic compound with a chemical structure similar to that of the endogenous amino acid homotaurinate, approved for the maintenance of alcohol abstinence62
  • Atomoxetine (Strattera, Lilly USA), an SNRI indicated for the treatment of ADHD63
  • Intrathecal baclofen (Gablofen, Mallinckrodt), a gamma-aminobutyric acid (GABA)-ergic agonist indicated for use in the management of severe spasticity of cerebral or spinal origin64
  • DMXB-A, a derivative of the nemertine toxin anabasein,65 which is being studied for the treatment of severe ASD-associated tactile defensiveness61
  • EPI-743 (vincerinone, Edison Pharmaceuticals), a member of the para-benzoquinone class of drugs, which was originally developed for the treatment of patients with inherited mitochondrial diseases66
  • RG7314 (Roche), an investigational small-molecule antagonist of the V1A vasopressin receptor, which has been implicated in modulating emotional processing and social deficits in patients with ASD59


Although numerous medications are used to treat the symptoms of ASD, such as irritability, aggression, and aberrant social behavior, only risperidone and aripiprazole are FDA-approved for ASD patients. Limited clinical data have supported treatment with SSRIs, CNS stimulants, NMDA-receptor antagonists, and other agents, but well-designed trials in larger cohorts are needed.

Irritability and Aggression

Risperidone and aripiprazole are FDA-approved for the treatment of irritability in children with ASD.4,8 Although clozapine can reduce aggression in ASD patients,14 its adverse effects—including significant weight gain, metabolic syndrome, and tachycardia—have limited its use in that setting.15 Haloperidol has been shown to be effective in treating ASD-related irritability and aggression,20,22 but treatment has been associated with persistent dyskinesias and extrapyramidal symptoms.17

Aberrant Social Behavior

In comparison studies,26,27 risperidone was generally more effective than haloperidol in treating aberrant social behavior in ASD patients, with fewer adverse effects. Oxytocin nasal spray has been shown to improve measures of emotion recognition and eye gaze as well as social impairments in patients with ASD.2830 Secretin, on the other hand, showed no clinical benefit in numerous ASD trials and is not recommended for this indication.35,36

Hyperactivity and Attention

Studies of methylphenidate in patients with ADHD and PDDs showed improvements in attention, hyperactivity, and impulsivity.3941 Similarly, venlafaxine improved attention and self-injurious behaviors in a series of case reports.43

Repetitive Behaviors

Standard fluoxetine improved repetitive behaviors (obsessive-compulsive symptoms) in adults with ASD,25 but a melt-in-the-mouth formulation of the drug was no more effective than placebo in children.45 Citalopram provided no benefit in a randomized controlled trial of children with ASD,47 but bumetanide showed some efficacy in a small European trial.48 The latter drug, a loop diuretic, can cause profound diuresis.48


Memantine was found to be ineffective in improving cognition in children with ASD.51 Rivastigmine, on the hand, provided significant improvements in this setting.52


Mirtazapine improved insomnia in children and adults with ASD and other developmental disorders.55 Similarly, a controlled-release formulation of melatonin, in addition to cognitive-behavioral therapy, improved sleep latency as early as one week in a 14-week study.56


While risperidone and aripiprazole remain the mainstays of ASD treatment, they are FDA-approved only for managing the irritability associated with the disorder. Clinical trials, therefore, have evaluated an array of pharmacological treatments in patients with ASD and related PDDs, and have provided clinicians with numerous off-label options. These treatments should be administered based on individual patient need, with due consideration being given to potential risks as well as benefits.


Ongoing U.S. Clinical Trials in Autism Spectrum Disorder (ASD) 61

Intervention Study Sponsor(s) Description Start Date Estimated Completion Date
Acamprosate (Campral, Forest Pharmaceuticals) Study of Acamprosate in Autism Children’s Hospital Medical Center, Cincinnati, Ohio 26-week, randomized, double-blind, placebo-controlled, phase 2 trial in 36 patients (ages 5–17 years) April 2013 February 2016
Atomoxetine (Strattera, Lilly) Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism Massachusetts General Hospital, Boston, Massachusetts 8-week, randomized, double-blind, placebo-controlled, cross-over, phase 3 trial in 86 patients (ages 5–15 years) July 2007 October 2015
Autologous umbilical-cord blood infusion Autologous Umbilical Cord Blood Infusion for Children With ASD Duke University, Durham, North Carolina 52-week, prospective, phase 1 trial in 20 patients (ages 2–6 years) June 2014 July 2016
Baclofen, intrathecal (Gablofen, Mallinckrodt) Open-Label Treatment of Severe Tactile Defensiveness and ASD With Intrathecal Baclofen University of Missouri, Columbia Open-label trial in 5 patients (ages 10–65 years) September 2014 June 2017
DMXB-A (nicotinic agonist) Phase I Nicotinic Agonist Treatment Trial for Autism University of Colorado, Denver Open-label, phase 1 trial in 20 patients (ages 18–50 years) August 2015 August 2018
Buspirone Open-Label Trial of Buspirone for Treatment of Anxiety in Youth With ASD Massachusetts General Hospital, Boston, Massachusetts Exploratory 8-week pilot study in 40 patients (ages 6–17 years) July 2013 April 2016
Dextromethorphan hydrobromide/quinidine sulfate (Nuedexta) Nuedexta for Treatment of Adults With Autism Sutter Health, Sacramento, California 8-week, randomized, double-blind, placebo-controlled, cross-over, phase 2 trial in 20 patients (ages 18–60 years) June 2012 September 2015
Divalproex Treatment of Children With ASDs and Epileptiform EEG With Divalproex Sodium Children’s Hospital, Boston, Massachusetts 12-week, randomized, double-blind, placebo-controlled, cross-over, phase 2 trial in 30 patients (ages 4–8 years) April 2014 April 2016
Donepezil Trial of the Drug Donepezil for Sleep Enhancement and Behavioral Change in Children With Autism National Institute of Mental Health Randomized, double-blind, placebo-controlled, phase 2 trial in 90 patients (ages 22–44 months) June 2013 September 2017
EPI-743 (vincerinone) Exploratory Open-Label Study of EPI-743 (Vincerinone) in Children With ASD Edison Pharmaceuticals, California 24-week, open-label, phase 2 trial in 20 patients (ages 3–14 years) October 2014 January 2016
Folinic acid Folinic Acid Intervention for ASDs University of Arkansas, Little Rock 12-week, randomized, double-blind, placebo-controlled, phase 2 trial in 192 patients (ages 3–14 years) May 2012 September 2015
Mecasermin (Increlex, Ipsen) Treatment of Rett Syndrome With Recombinant Human IGF-1 Children’s Hospital, Boston, Massachusetts 40-week, randomized, double-blind, placebo-controlled, phase 2 trial in 30 patients (ages 2–10 years) January 2013 December 2015
Memantine Multi-Site Double-Blind Placebo-Controlled Trial of Memantine Versus Placebo in Children With Autism Targeting Memory and Motor Planning (MEM) Mount Sinai School of Medicine; Rush University Medical Center; Nationwide Children’s Hospital; Ohio State University 24-week, randomized, double-blind, placebo-controlled, phase 2 trial in 60 patients (ages 6–12 years) December 2011 August 2015
Methylphenidate (extended release) Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD Massachusetts General Hospital, Boston, Massachusetts 6-week, open-label, phase 4 trial in 40 patients (ages 18–25 years) May 2014 July 2015
Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study Seattle Children’s Hospital, Seattle, Washington 6-week, randomized, single-blind, phase 4 trial in 25 patients (ages 6–16 years) September 2014 December 2016
Oxytocin nasal spray Intranasal Oxytocin and Learning in Autism Children’s Hospital of Philadelphia, Pennsylvania 12-day, randomized, double-blind, placebo-controlled, phase 2 trial in 68 patients (ages 12–17 years) September 2011 April 2015
Randomized, Controlled Trial of Intranasal Oxytocin as Adjunct to Behavioral Therapy for ASD Massachusetts General Hospital, Boston, Massachusetts Randomized, placebo-controlled, phase 2 interventional trial in 150 patients (ages 18–30 years) April 2014 September 2016
Open-Label Trial of Oxytocin in Adolescents With ASD 8-week, open-label trial in 40 patients (ages 11–17 years) October 2013 November 2016
Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors (SOARS-B) University of North Carolina, Chapel Hill Randomized, double-blind, placebo-controlled, phase 2 trial in 300 patients (ages 3–17 years) August 2014 October 2017
Brain Imaging of Intranasal Oxytocin Treatment in Autism Randomized, double-blind, phase 1 trial in 28 patients (ages 6–18 years) September 2014 February 2018
Rapalogues (sirolimus or everolimus) Rapalogues for Autism Phenotype in Tuberous Sclerosis Complex (TSC): A Feasibility Study (RAPT) Hugo W. Moser Research Institute, Baltimore, Maryland 53-week, open-label, phase 2 trial in 3 patients (ages 2–30 years) July 2013 December 2015
RG7314 (vasopressin V1A receptor antagonist) Study of RG7314 to Investigate Efficacy and Safety in Individuals With ASDs Hoffmann-LaRoche 12-week, randomized, double-blind, parallel-group, placebo-controlled, proof-of-concept trial in 155 patients (ages 18–45 years) September 2013 August 2015
Riluzole Pilot Study of Riluzole for Drug-Refractory Irritability in ASD Children’s Hospital Medical Center, Cincinnati, Ohio 14-week, randomized, double-blind, placebo-controlled, crossover, phase 2/3 trial in 12 patients (ages 12–25 years) June 2013 July 2015
STX209 (arbaclofen) Magnetoencephalographic (MEG) Study of STX209 Children’s Hospital of Philadelphia, Pennsylvania Randomized, double-blind, placebo-controlled trial in 8 patients (ages 14–17 years); five weekly visits October 2014 December 2016
Vitamin D3 Open Label Clinical Trial of Vitamin D in Children With Autism University of California, San Francisco Open-label, phase 2/3 trial in 20 patients (ages 3–8 years) February 2012 December 2015
Author bio: 
Dr. LeClerc is a PGY1 Pharmacy Resident at Saint Vincent Hospital in Erie, Pennsylvania. Dr. Easley is an Assistant Professor of Pharmacy Practice at the Union University School of Pharmacy in Jackson, Tennessee. Disclosure: The authors report no commercial or financial interests in regard to this article.


  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 5th edArlington, Virginia: American Psychiatric Publishing. 2013;
  2. Autism Speaks. What is autism?. 2015;Available at: Accessed February 6, 2015
  3. Rice CE, Baio J, Van Naarden Braun K, et al. A public health collaboration for the surveillance of autism spectrum disorders. Paediatr Perinat Epidemiol 2007;21:179–190.
  4. Food and Drug Administration. FDA approves the first drug to treat irritability associated with autism, Risperdal. October 62006;Available at: Accessed January 27, 2015
  5. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314–321.
  6. Troost PW, Lahuis BE, Steenhuis MP, et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 2005;44:1137–1144.
  7. Sharma A, Shaw S. Efficacy of risperidone in managing maladaptive behaviours for children with autistic spectrum disorder: a meta-analysis. J Pediatr Healthcare 2012;264:291–299.
  8. Bristol-Myers Squibb. U.S. Food and Drug Administration approves Abilify (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients (ages 6 to 17 years). November 202009;Available at: Accessed January 28, 2015
  9. Abilify (aripiprazole) prescribing information Princeton, New Jersey: Bristol-Myers Squibb. December 2014;Available at: Accessed January 28, 2015
  10. Marcus RN, Owen R, Manos G, et al. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. J Clin Psychiatry 2011;72:1270–1276.
  11. Varni JW, Handen BL, Corey-Lisle PK, et al. Effect of aripiprazole 2 to 15 mg/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post hoc analysis of two controlled trials. Clin Ther 2012;34:980–992.
  12. Ching H, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012;May 165:CD00904310.1002/14651858.CD009043.pub2
  13. Clozaril (clozapine) prescribing information East Hanover, New Jersey: Novartis Pharmaceuticals Corporation. December 2014;Available at: Accessed January 28, 2015
  14. Beherec L, Lambrey S, Quilici G, et al. Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors. J Clin Psychopharmacol 2011;31:341–344.
  15. Posey DJ, McDougle CJ. Use of atypical antipsychotics in autism. In: Hollander E. Autism Spectrum Disorders New York, New York: Marcel Dekker, Inc. 2003;247–264.
  16. Smith HS, Cox LR, Smith BR. Dopamine receptor antagonists. Ann Palliative Med July 2012;Available at: Accessed January 28, 2015
  17. Haldol (haloperidol) prescribing information Raritan, New Jersey: Ortho-McNeil Pharmaceutical, Inc.. June 2009;Available at: Accessed January 27, 2015
  18. MacDonald K, Wilson MP, Minassian A, et al. A retrospective analysis of intramuscular haloperidol and olanzapine in the treatment of agitation in drug- and alcohol-using patients. Gen Hosp Psychiatry 2010;32:443–445.
  19. Clinton JE, Sterner S, Stelmachers Z, et al. Haloperidol for sedation of disruptive emergency patients. Ann Emerg Med 1987;16:319–322.
  20. Faretra G, Dooher L, Dowling J. Comparison of haloperidol and fluphenazine in disturbed children. Am J Psychiatry 1970;126:1670–1673.
  21. Perry R, Campbell M, Adams P, et al. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 1989;28:87–92.
  22. Remington G, Sloman L, Konstantareas M, et al. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol 2001;21:440–444.
  23. Zoloft (sertraline) prescribing information New York, New York: Pfizer Inc.. May 2014;Available at: Accessed January 29, 2015
  24. Bhardwaj A, Agarwal V, Sitholey P. Asperger’s disorder with co-morbid separation anxiety disorder: a case report. J Autism Dev Disord 2005;35:135–136.
  25. Hollander E, Soorya L, Chaplin W, et al. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. Am J Psychiatry 2012;169:292–299.
  26. Miral S, Gencer O, Inal-Emiroglu FN, et al. Risperidone versus haloperidol in children with AD: a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry 2008;17:1–8.
  27. Gencer OF, Neslihan IE, Miral S, et al. Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. Eur Child Adolesc Psychiatry 2008;17:217–225.
  28. Lee H-J, Macbeth AH, Pagani J, ScottWS3rdOxytocin: the great facilitator of life. Prog Neurobiol 2009;88:127–151.
  29. Liu JCJ, McErlean RA, Dadds MR. Are we there yet? The clinical potential of intranasal oxytocin in psychiatry. Curr Psychiatry Rev 2012;8:37–48.
  30. Gordon I, Vander Wyka BC, Bennetta RH, et al. Oxytocin enhances brain function in children with autism. PNAS 2013;110:20953–20958.
  31. Preti A, Melis M, Siddi S, et al. Oxytocin and autism: A systematic review of randomized controlled trials. J Child and Adolesc Psychopharmacology 2014;24:54–68.
  32. Guastella AJ, Einfeld SL, Gray KM, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 2010;67:692–694.
  33. Kosaka H, Munesue T, Ishitobi M, et al. Long-term oxytocin administration improves social behaviors in a girl with autistic disorder. BMC Psychiatry 2012;12:11010.1186/1471-244X-12-110
  34. Chu JYS, Yung WH, Chow BKC. Secretin: a pleiotrophic hormone. Ann N.Y. Acad Sci 2006;1070:27–50.
  35. Agency for Healthcare Research and Quality. Therapies for children with autism spectrum disorders. Comparative effectiveness review no. 26April 2011;Available at: Accessed January 29, 2015
  36. Williams K, Wray JA, Wheeler DM. Intravenous secretin for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012;Apr 184:CD00349510.1002/14651858.CD003495.pub3
  37. Ritalin (methylphenidate) prescribing information East Hanover, New Jersey: Novartis Pharmaceuticals Corporation. December 2013;Available at: Accessed January 29, 2015
  38. Concerta (extended-release methylphenidate) prescribing information Titusville, New Jersey: Janssen Pharmaceuticals, Inc.. December 2013;Available at: Accessed January 29, 2015
  39. Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 2000;30:245–255.
  40. Posey DJ, Aman MG, McCracken JT, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry 2007;61:538–544.
  41. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005;62:1266–1274.
  42. Effexor XR (extended-release venlafaxine hydrochloride) prescribing information Philadelphia, Pennsylvania: Wyeth Pharmaceuticals Inc. December 2014;Available at: Accessed January 30, 2015
  43. Carminati GG, Deriaz N, Bertschy G. Low-dose venlafaxine in three adolescents and young adults with autistic disorder improves self-injurious behavior and attention deficit/hyperactivity disorders (ADHD)-like symptoms. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:312–315.
  44. Prozac (fluoxetine) prescribing information Indianapolis, Indiana: Eli Lilly and Company. July 2014;Available at: Accessed January 30, 2015
  45. Autism Speaks. Autism Speaks announces results reported for the Study of Fluoxetine in Autism (SOFIA). February 182009;Available at: Accessed January 30, 2015
  46. Celexa (citalopram) proposed labeling text St. Louis, Missouri: Forest Laboratories. January 2009;Available at:,021046s015lbl.pdf. Accessed January 30, 2015
  47. King BH, Hollander E, Sikich L, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 2009;66:583–590.
  48. U.S. National Library of Medicine. Bumetanide–bumetanide injection: drug label information. December 2009;Available at: Accessed February 2, 2015
  49. Lemonnier E, Degrez C, Phelep M, et al. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry 2012;2:e20210.1038/tp.2012.124
  50. Namenda (memantine) prescribing information St. Louis, Missouri: Forest Pharmaceuticals. October 2013;Available at: Accessed February 2, 2015
  51. Owley T, Salt J, Guter S, et al. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006;16:517–524.
  52. Exelon (rivastigmine) prescribing information East Hanover, New Jersey: Novartis Pharmaceuticals Corporation. October 2013;Available at: Accessed February 3, 2015
  53. Chez MG, Aimonovitch M, Buchanan T, et al. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol 2004;19:165–169.
  54. Remeron (mirtazapine) prescribing information Whitehouse Station, New Jersey: Merck & Comany, Inc.. September 2012;Available at: Accessed February 3, 2015
  55. Posey DJ, Guenin KD, Kohn AE, et al. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol 2011;11:267–277.
  56. Cortesi F, Giannotti F, Sebastiani T, et al. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res 2012;21:700–709.
  57. Zhdanova IV, Lynch HJ, Wurtman RJ. Melatonin: a sleep-promoting hormone. Sleep 1997;20:899–907.
  58. Malow B, Adkins KW, McGrew SG, et al. Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes. J Autism Dev Disord 2012;42:1729–1737.
  59. Roche. Product development portfolio. January 282015;Available at: Accessed February 6, 2015
  60. Autism Speaks. Strategic plan for science 2013–2017. January 252013;Available at: Accessed February 6, 2015
  61. National Institutes of Health. Available at: Accessed February 4, 2015
  62. Campral (delayed-release acamprosate calcium) prescribing information St. Louis, Missouri: Forest Pharmaceuticals, Inc.. January 2012;Available at: Accessed February 6, 2015
  63. Strattera (atomoxetine) prescribing information Indianapolis, Indiana: Eli Lilly and Company. January 2015;Available at: Accessed February 6, 2015
  64. Gablofen (baclofen injection) prescribing information Hazelwood, Missouri: Mallinckrodt Brand Pharmaceuticals, Inc.. October 2013;Available at: Accessed February 6, 2015
  65. Kem W, Soti F, Wildeboer K, et al. The nemertine toxin anabaseine and its derivative DMXBA (GTS-21): Chemical and pharmacological properties. Mar Drugs 2006;4:255–273.
  66. Edison Pharmaceuticals. Edison Pharmaceuticals announces initiation of EPI-743 Pearson syndrome clinical trial. March 172014;Available at: Accessed February 6, 2015
  67. Kumar B, Prakash A, Sewal RK, et al. Drug therapy in autism: a present and future perspective. Parmacol Rep 2012;64:1291–1304.